ABvac40

About Araclon Biotech

Araclon Biotech, founded in 2004 and based in Zaragoza, Spain, is a Grifols subsidiary dedicated to tackling Alzheimer's Disease through early diagnostics and active immunotherapy. Its core technology platform centers on measuring amyloid-beta peptides (Aβ40 and Aβ42) in blood plasma, providing a less invasive alternative to cerebrospinal fluid or PET imaging for early detection. The company's lead therapeutic candidate, ABvac40, is an active vaccine targeting the Aβ40 peptide, and it has begun preclinical research into Parkinson's disease through a collaboration with the Spanish National Research Council (CSIC). As a fully integrated R&D unit within Grifols, Araclon leverages its parent company's resources while pursuing a high-risk, high-reward strategy in the neurodegenerative disease space.

Therapeutic Areas

Other Alzheimer's Disease Drugs